Reduction of hyperbilirubinemia with hypericum extract (St. John's Wort) in a patient with Crigler-Najjar syndrome type II

4Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aims: Crigler-Najjar syndrome (CN) type II is a congenital disease with unconjugated hyperbilirubinemia due to a deficiency of uridine 5′-diphospho-glucuronosyltransferase 1A1. Since the currently proposed treatment with phenobarbital is associated with adverse reactions, we investigated the effect of hypericum extract. Methods: Repetitive determination of total serum bilirubin in a female with CN type II before, during and after daily treatment with 900 mg hypericum extract on two occasions for 8 weeks. Confirmation of the enzyme-inducing effect of hypericum using the cytochrome P450 3A4 probe drug i.v. midazolam. Results: Hypericum reduced midazolam exposure by 42% and the total serum bilirubin concentration by 30 to 35%. Conclusions: Hypericum extract is a potential alternative to phenobarbital in patients with CN type II.

Cite

CITATION STYLE

APA

Kummer, O., Hammann, F., Haschke, M., & Krähenbühl, S. (2016). Reduction of hyperbilirubinemia with hypericum extract (St. John’s Wort) in a patient with Crigler-Najjar syndrome type II. British Journal of Clinical Pharmacology, 81(5), 1002–1004. https://doi.org/10.1111/bcp.12869

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free